Abstract
Patients with end-stage kidney disease have underlying platelet dysfunction and often receive anti-platelet and anticoagulant medications for various systemic diseases. The combination of these factors makes them more prone to bleeding complications. Anticoagulants and thrombolytics are used during endovascular procedures performed on dialysis vascular access. Planning interventional procedures in patients receiving warfarin, anti-platelet agents, and high-dose heparin requires better understanding of pharmacology to minimize the risks of bleeding post-procedure. The addition of newer direct oral anticoagulants to the list has increased the complexity of pre-procedure assessment. We discuss the safety and risks involved while performing interventions on patients who are receiving these agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, American College of Chest Physicians SO Chest. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):141S.
Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart Association. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994.
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385.
Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81–8.
Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502.
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28(1):82–5.
de Sancho M, Lema MG, Amiral J, Rand J. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. Thromb Haemost. 1996;75(4):695–6.
O’shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg. 2003;38(3):541–8.
United States renal data system: cardiovascular special studies. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda; 2005.
Lee O, Raque JD, Lee LJ, Wivell W, Block CA, Bettmann MA. Retrospective assessment of risk factors to predict tunneled hemo-dialysis catheter outcome. J Vasc Interv Radiol. 2004;15(5):457–61.
Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemo-dialysis: a randomized controlled trial. J Am Soc Nephrol. 2002;13(9):2331.
Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y. Antiphospholipids in hemo-dialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995;48(3):794.
Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995;26(2):347.
Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int. 2005;68(3):1223.
Abigail Falk MD, Harold Mitty MD, Jeffrey Guller MD, Victoria Teodorescu MD, Jaime Uribarri MD, Joseph Vassalotti MD. Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator. J Vasc Interv Radiol. 2001;12(3):305–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Maditz, R., Anvari, E., Vachharajani, T.J. (2022). Anticoagulants and Thrombolytics. In: Yevzlin, A.S., Asif, A., Salman, L., Ramani, K., Qaqish, S.S., Vachharajani, T.J. (eds) Interventional Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-030-81155-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-81155-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-81154-9
Online ISBN: 978-3-030-81155-6
eBook Packages: MedicineMedicine (R0)